Lisocabtagene maraleucel (LISO‐CEL) versus standard of care (SOC) as second‐line therapy in large B‐cell lymphoma (TRANSFORM study): Subgroup analyses by prior therapy response Meeting Abstract
| Authors: | Tobin, J. W.; Jurinovic, V.; Tsang, H.; Roos, D.; Tsang, R.; Macann, A.; Davis, S.; Christie, D.; Law, S.; Nath, K.; Sabdia, M.; Patch, A. M.; Gunawardana, J.; Merida de Long, L.; Hoster, E.; Horn, H.; Shanavas, M.; Li, L.; Cheah, C.; Benhur, A.; Hou, M.; O'Brien, P.; Johnston, A. M.; Cochrane, T.; Butler, J.; Thompson, E.; Blombery, P.; Seymour, J. F.; Gandhi, M. K.; MacManus, M. |
| Abstract Title: | Lisocabtagene maraleucel (LISO‐CEL) versus standard of care (SOC) as second‐line therapy in large B‐cell lymphoma (TRANSFORM study): Subgroup analyses by prior therapy response |
| Meeting Title: | 17th International Conference on Malignant Lymphoma (ICML) |
| Journal Title: | Hematological Oncology |
| Volume: | 41 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Jun 13-17 |
| Meeting Location: | Lugano, Switzerland |
| ISSN: | 0278-0232 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2023-06-01 |
| Start Page: | 216 |
| End Page: | 217 |
| Language: | English |
| DOI: | 10.1002/hon.3163_140 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: 140 -- Source: Cinahl |
